肯尼亚西部疟疾流行地区医务人员对青蒿琥酯-咯萘啶和奎宁治疗方案及剂量的了解。

Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.

机构信息

Department of Public Health, Maseno University, Private Bag, Maseno, Kenya.

出版信息

Malar J. 2012 Dec 29;11:436. doi: 10.1186/1475-2875-11-436.

Abstract

BACKGROUND

Due to widespread anti-malarial drug resistance in many countries, Kenya included, artemisinin-based Combination Therapy (ACT) has been adopted as the most effective treatment option against malaria. Artemether-lumefantrine (AL) is the first-line ACT for treatment of uncomplicated malaria in Kenya, while quinine is preferred for complicated and severe malaria. Information on the providers' knowledge and practices prior to or during AL and quinine implementation is scanty. The current study evaluated providers' knowledge and practices of treatment policy and dosing regimens with AL and quinine in the public, private and not-for-profit drug outlets.

METHODS

A cross-sectional survey using three-stage sampling of 288 (126 public, 96 private and 66 not-for-profits) providers in drug outlets was conducted in western Kenya in two Plasmodium falciparum-endemic regions with varying malarial risk. Information on provider in-service training, knowledge (qualification, treatment policy, dosing regimen, recently banned anti-malarials) and on practices (request for written prescription, prescription of AL, selling partial packs and advice given to patients after prescription), was collected.

RESULTS

Only 15.6% of providers in private outlets had received any in-service training on AL use. All (100%) in public and majority (98.4%) in not-for-profit outlets mentioned AL as first line-treatment drug. Quinine was mentioned as second-line drug by 47.9% in private outlets. A total of 92.0% in public, 57.3% in private and 78.8% in not-for-profit outlets stated correct AL dose for adults. A total of 85.7% of providers in public, 30.2% in private and 41.0% in not-for-profit outlets were aware that SP recommendations changed from treatment for mild malaria to IPTp in high risk areas. In-service training influenced treatment regimen for uncomplicated malaria (P = 0.039 and P = 0.039) and severe malaria (P < 0.0001 and P = 0.002) in children and adults, respectively. Most (82.3%) of private outlets sell partial packs of AL while 72.4% do not request for written prescription for AL. In-service training influenced request for written prescription (P = 0.001), AL prescription (P < 0.0001) and selling of partial packs (P < 0.0001).

CONCLUSION

Public-sector providers have higher knowledge on treatment policy and dosing regimen on recommended anti-malarials. Changes in treatment guidelines should be accompanied by subsequent implementation activities involving all sector players in unbiased strategies.

摘要

背景

由于许多国家(包括肯尼亚)普遍存在抗疟药物耐药性,青蒿素为基础的联合疗法(ACT)已被作为治疗疟疾的最有效选择。青蒿琥酯-咯萘啶(AL)是肯尼亚治疗无并发症疟疾的一线 ACT,而奎宁则是治疗复杂和严重疟疾的首选药物。关于在实施 AL 和奎宁之前或期间提供者的知识和实践情况的信息很少。本研究评估了在西部肯尼亚两个恶性疟原虫流行地区,公共、私人和非营利性药物销售点提供者对 AL 和奎宁治疗政策和剂量方案的知识和实践。

方法

采用三阶段抽样方法,对 288 名(公共 126 名,私人 96 名,非营利性 66 名)提供者进行了横断面调查,这些提供者在疟疾风险不同的两个地区的药物销售点工作。收集了提供者在职培训、知识(资格、治疗政策、剂量方案、最近被禁止的抗疟药物)和实践(要求书面处方、开具 AL 处方、销售部分包装和开具处方后向患者提供建议)方面的信息。

结果

只有 15.6%的私人诊所提供者接受过任何关于使用 AL 的在职培训。所有(100%)公共和大多数(98.4%)非营利性销售点均将 AL 作为一线治疗药物。奎宁被 47.9%的私人诊所列为二线药物。公共、私人和非营利性销售点中,共有 92.0%、57.3%和 78.8%的人表示知道成人 AL 的正确剂量。公共部门 85.7%、私人部门 30.2%和非营利性部门 41.0%的提供者知道 SP 建议从治疗轻度疟疾改为高危地区的 IPTp。在职培训分别影响儿童和成人的无并发症疟疾(P=0.039 和 P=0.039)和严重疟疾(P<0.0001 和 P=0.002)的治疗方案。82.3%的私人销售点出售 AL 的部分包装,而 72.4%的销售点不要求开具 AL 的书面处方。在职培训影响了书面处方的要求(P=0.001)、AL 处方的开具(P<0.0001)和部分包装的销售(P<0.0001)。

结论

公共部门提供者对推荐的抗疟药物的治疗政策和剂量方案有更高的了解。治疗指南的改变应伴随着后续的实施活动,涉及所有部门的参与者,采取公正的策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索